PTC Therapeutics (PTCT) Crushes Q2 2026 with a 171% EPS Beat
As seen on the 24/7 Wall St. homepage on July 30, 2026.
PTC Therapeutics crushed Q2 earnings with a 171% EPS beat on blockbuster Sephience revenue that more than doubled sales year-over-year, prompting management to lift full-year product revenue guidance by $100 million. The phenylketonuria therapy generated $151.3 million in Q2 with 1,647 patients on therapy globally, while a $50 million Novartis milestone from the votoplam Huntington's study provided additional lift.
Continue ReadingShow less
PTC Therapeutics reported Q2 2026 earnings per share of $0.92 against an analyst estimate of $0.34, a beat of roughly 171%. Total revenue came in at $360.5 million, topping estimates of $298.6 million by about 21% and marking the company's strongest quarterly revenue figure outside of the anomalous Q1 2025 spike. The results were powered almost entirely by Sephience, the company's phenylketonuria therapy, which generated $151.3 million in the quarter with 1,647 patients on the drug globally.
The Sephience launch drove sales that more than doubled on a year-over-year basis, a pace that clearly caught Wall Street off-guard. Adding to the quarter's lift was a $50 million milestone payment from Novartis tied to the votoplam Huntington's disease study, which provided a meaningful one-time boost to the top line. Management responded to the momentum by raising full-year product revenue guidance by $100 million.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Looking at the revenue trend, the Q2 2026 result of $360.5 million continues a sharp acceleration that began in Q1 2026 at $272.6 million, a meaningful step up from the $164.7 million reported in Q4 2025. Investors will be watching whether Sephience's patient growth and Novartis pipeline milestones can sustain that trajectory into the second half of the year.
Mentioned: PTCT